WILLIAM SIMPSON: Open Payments
NPI 1144879628 · PORTLAND, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,067 in 40 payments from 20 companies in 2025. Trend: 2023 $1,639 · 2024 $1,313 · 2025 $1,067
Food & beverage: $1,062Education: $5
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 4 | $207 |
| ConvaTec Inc. | 4 | $99 |
| PFIZER INC. | 4 | $84 |
| Ferring Pharmaceuticals Inc. | 3 | $70 |
| Olympus America Inc. | 3 | $66 |
| AstraZeneca Pharmaceuticals LP | 2 | $63 |
| Dendreon Pharmaceuticals LLC | 2 | $59 |
| Myriad Genetic Laboratories, Inc. | 3 | $59 |
| Merck Sharp & Dohme LLC | 2 | $50 |
| Janssen Biotech, Inc. | 2 | $46 |
Products named: GEMTESA, XTANDI, GENTLECATH GLIDE, ADSTILADRIN, iTIND System, LYNPARZA, PROVENGE, PROLARIS.
Industry payments across OR — which companies pay providers there.
